(CBMG) |
| 0 (0%) 10-10 19:06 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 23.08 |
| Resistance 1: | 19.76 |
| Pivot price: | 19.70 |
| Support 1: | 18.43 |
| Support 2: | 17.60 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -2.830 |
| Book Value | 0.890 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.014 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -17044.12 |
| Return on Assets (ttm) | -34.7 |
| Return on Equity (ttm) | -129.9 |
Company news
Fri, 15 Dec 2023
Cellular Biomedicine draws a line under its past | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Wed, 03 May 2023
Janssen Biotech signs licence deal with CBMG for CAR-T cancer therapies - Pharmaceutical Technology
Tue, 02 May 2023
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies - BioSpace
Wed, 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - BioSpace
Wed, 12 Jan 2022
FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL - OncLive
Thu, 30 Sep 2021
CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
